The Future Of Gene Therapy Production: Enriching Full Capsids, Reducing Costs

Gene therapy’s promise hinges on the ability to produce potent, safe, and cost-effective viral vectors, yet current manufacturing methods often fall short. AAV preparations frequently contain high levels of empty or partial capsids, which can trigger immune responses, reduce therapeutic efficacy, and drive up costs due to increased dosing requirements.

Explore how VintaBio’s intensified upstream process, built on proven adherent culture methods, enriches full capsids while minimizing impurities. By extending cell culture duration, the platform significantly reduces nonfunctional capsids before downstream processing, offering a scalable solution that enhances productivity and lowers manufacturing costs.

Gain a deeper understanding of full capsid kinetics, learn how process intensification improves patient safety, and discover how regulatory-compliant adherent technologies can be harnessed for scalable gene therapy production. If you're looking to optimize AAV manufacturing without compromising quality or budget, this session offers valuable insights worth exploring.